

# Performance Improvement Strategies in Colorectal Cancer Patient Data Form

**Instructions:** Complete a separate patient data form for each patient. If the information is not found in the chart, select the "No" box. Fax your completed forms (toll-free) to 866 419 5789 or submit online at [www.pi-iq.com/crc](http://www.pi-iq.com/crc). \* Indicates required fields.

## Patient Data

Date of initial CRC-related visit: \_\_\_\_\_ Date of last CRC-related visit: \_\_\_\_\_ Chart format:  EMR  Paper-based

Cancer type:  Stage II colon  Stage III colon  Stage IV colon  Stage II rectal  Stage III rectal  Stage IV rectal

Time since diagnosis:  Less than 1 year  1 to 3 years  3 to 4 years

Clinician Name: \_\_\_\_\_ Form completed by:  Clinician  Designee

## Benchmark 1: Patient Safety/Supportive Care

1. Was a copy of the surgical pathology report included in the patient's chart?  Yes  No
2. Is TNM staging information documented in the chart?  Yes  No
3. Did the patient have a complete evaluation of the colon (colonoscopy or barium enema) within 12 months of diagnosis?  Yes  No
- \* 4. Does the patient's chart include quantified pain assessments from every visit?  Yes  No  Pain assessments recorded the last \_\_\_ visits only
- \* 5. Does the patient's chart include information regarding their emotional well-being?  Yes  No

## Benchmark 2: Evidence-Based Surveillance

6. Was a blood test for CEA performed at least once before surgery was performed or chemotherapy was given?  Yes  No  N/A, no surgery or chemotherapy
7. Was a blood test for CEA performed at least once 6 months **after** surgery or chemotherapy?  Yes  No  N/A, no surgery or chemotherapy
8. Was a blood test for CEA performed more than once following surgery or chemotherapy?  Yes  No  N/A, no surgery or chemotherapy
9. Was the number of evaluated lymph nodes recorded in the chart?  Yes \_\_\_\_\_ nodes recorded  No
- \* 10. Was the number of evaluated lymph nodes included in staging considerations?  Yes  No  N/A, number of evaluated lymph nodes is unknown
- \* 11. Was an annual chest and abdomen CT ordered and/or performed **after** primary treatment?  Yes  No  N/A, patient still undergoing primary treatment
12. Was a colonoscopy ordered and/or performed 3 years **after** primary treatment?  Yes  No  N/A, patient still undergoing treatment or is not yet 3 years from primary treatment

## Benchmark 3: Evidence-Based Treatment

13. If this patient has **stage III** colon or rectal cancer, was adjuvant chemotherapy recommended?  Yes  No  N/A, not stage III
14. If this patient has **stage II** colon or rectal cancer, was adjuvant chemotherapy discussed?  Yes  No  N/A, not stage II
15. For patients with **stage II/III** colon or rectal cancer who received adjuvant chemotherapy, did treatment begin within 8 weeks after surgical resection?  
 Yes  No  N/A, no adjuvant chemotherapy
16. For patients with stage II/III **rectal** cancer, was there a radiation referral within 6 months of diagnosis?  Yes  No  N/A, patient does not have stage II/III rectal cancer
17. For patients with stage II/III **colon** cancer, did the patient receive adjuvant chemotherapy with any of the following regimens:
  - 5-FU and leucovorin
  - Capecitabine
  - FLOX regimen including 5-FU, leucovorin, and oxaliplatin
  - FOLFOX regimen including 5-FU, leucovorin, and oxaliplatin
  - XELOX regimen including oxaliplatin and capecitabine Yes, patient received one of these regimens  No, patient received another regimen for chemotherapy  
 No, patient did not receive adjuvant chemotherapy  N/A, patient does not have stage II/III colon cancer
18. If this patient has mCRC with lymph node involvement, or penetration of the rectal wall, was chemotherapy recommended?  
 Yes  No  N/A, patient does not have mCRC with lymph node involvement or penetration of the rectal wall
19. If this patient has mCRC and documented liver only metastases, is a surgical referral included in the chart?  Yes  No  N/A, patient does not have resectable disease
20. Does this patient have mCRC and documented status of *KRAS*?  Yes  No  N/A, patient does not have mCRC
21. If this patient is receiving or has received treatment regimens that include cetuximab and panitumumab (alone or in combination), does he/she have documented status of wild-type *KRAS*?  
 Yes  No  N/A, patient does not have mCRC or has not been treated with cetuximab and/or panitumumab